These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 913979)

  • 1. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
    Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
    Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
    Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
    J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium).
    Roberts RK; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1978 Sep; 75(3):479-85. PubMed ID: 680505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theophylline disposition in patients with hepatic cirrhosis.
    Piafsky KM; Sitar DS; Rangno RE; Ogilvie RI
    N Engl J Med; 1977 Jun; 296(26):1495-7. PubMed ID: 865528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
    Saudek F; Morávek J; Modr Z
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine clearance is impaired in alcoholic cirrhosis.
    Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
    Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of liver disease in man on the disposition of phenobarbital.
    Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
    J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
    Hamberg O; Vilstrup H
    Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-order clearance of plasma galactose: the effect of liver disease.
    Henderson JM; Kutner MH; Bain RP
    Gastroenterology; 1982 Nov; 83(5):1090-6. PubMed ID: 7117792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
    Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis.
    Neugebauer G; Raedsch R; Stiehl A; Kaufmann B; Besenfelder E; Neubert P; Walter-Sack I
    Arzneimittelforschung; 1989 Oct; 39(10A):1343-7. PubMed ID: 2576360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and cerebrospinal fluid concentration of nafcillin in pediatric patients undergoing cerebrospinal fluid shunt placement.
    Nahata MC; Fan-Havard P; Kosnik EJ; Bartkowski MH; Barson WJ
    Chemotherapy; 1990; 36(2):98-102. PubMed ID: 2311446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.